MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to detect drug and alcohol impairment in real time using short speech samples. The technology, trained on over 50 million data points, analyzes more than 140 acoustic markers to assess impairment without the need for traditional breath, saliva, urine or laboratory testing. The company plans to deploy the system through Edge AI kiosks, with initial field testing scheduled for 2026 and a commercial focus on South American mining operations, where large-scale workforce screening is critical for safety and logistics.
The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry forecasts. MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers and healthcare. The company leverages its proprietary research to address increasing demand for faster, scalable workplace impairment detection solutions.
MindBio is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI model uses over 50 million data points to predict alcohol intoxication with notable accuracy using only the human voice. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detection in various environments including mining, aviation, construction and law enforcement.
For more information, visit the company’s newsroom at https://ibn.fm/MBQIF. The full article can be accessed at https://ibn.fm/Gw5Fa.
